Proxy Asks Shareholders to Approve 7.5M-Share Equity Plan at Nov 30 Meeting
INBP sits 20% above its 52-week low of $0.138.
Summary
Integrated BioPharma's definitive proxy asks shareholders at the November 30, 2026 annual meeting to approve a 2025 Equity Incentive Plan covering up to 7,500,000 shares — about a quarter of the 31,059,610 shares outstanding — alongside a routine director slate and auditor ratification.
Key Events · Corporate Governance and Compliance · INBP
-
Equity Plan Seeks 7.5M Shares
Shareholders vote November 30, 2026 on the 2025 Equity Incentive Plan authorizing up to 7,500,000 shares, with 6,773,500 shares remaining available as of June 30, 2026.
-
Dilution Scale vs Shares Outstanding
The 7,500,000 authorized shares equal about 24% of the 31,059,610 shares outstanding on the October 15, 2026 record date (7,500,000 / 31,059,610 = 24.1%).
-
Related-Party Rent Raised to $1.1M
The February 17, 2026 fourth lease amendment with Vitamin Realty — controlled 41% each by the Co-CEOs — cuts space to 110,095 sq ft but sets minimum annual rent of $1.1 million through January 31, 2029.
-
Meeting and Record Dates Set
Annual meeting is November 30, 2026 at 9:00 a.m. in Hillside, New Jersey; holders of record on October 15, 2026 are entitled to vote.
Analysis · INBP · Life Sciences
The headline item is a request to authorize up to 7,500,000 shares under the 2025 Equity Incentive Plan — roughly a quarter of the 31,059,610 shares outstanding on the October 15 record date. Approval would meaningfully expand the equity overhang at a $0.165 stock price. The proxy also puts the amended Vitamin Realty lease on the record: rent on the Hillside facility rises to $1.1 million a year through January 2029, a real cash commitment for a company that just posted a $2.8M net loss and a PNC covenant breach in FY2026. Board control is effectively settled — the DeSantis, Kay and Sheppard family holdings plus the Estate of E. Gerald Kay cover most of the register — so the director slate and auditor ratification are formalities. The equity plan vote is the one with economic consequences.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 30.7% of the 1698 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INBP was trading at $0.17 on OTC in the Life Sciences sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $0.14 to $0.42. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.